Whilst some caution the use of SGLT2 inhibitors in people with active DFU, we consider that an individualised person centred-approach be adopted in people with heart failure and/or CKD where the uncertain, and possibly low risk, of exacerbating the DFU is balanced with the benefits of SGLT2 inhibitor use [130]. Here, SLC5A2 is linked to heart failure.